Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 May;34(5):1450-1453.
doi: 10.1038/s41375-019-0675-6. Epub 2019 Dec 11.

Familial myeloid malignancies with germline TET2 mutation

Nicolas Duployez  1   2 , Laure Goursaud  3 , Laurène Fenwarth  4   5 , Claire Bories  6 , Alice Marceau-Renaut  4   5 , Thomas Boyer  4   5 , Elise Fournier  4   7 , Olivier Nibourel  4   5 , Catherine Roche-Lestienne  5   8 , Guillemette Huet  5   9 , David Beauvais  3 , Céline Berthon  5   3 , Nathalie Cambier  3   10 , Bruno Quesnel  5   3 , Claude Preudhomme  4   5
Affiliations
Case Reports

Familial myeloid malignancies with germline TET2 mutation

Nicolas Duployez et al. Leukemia. 2020 May.
No abstract available

PubMed Disclaimer

References

    1. Delhommeau F, Dupont S, Valle VD, James C, Trannoy S, Masse A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360:2289–301. - DOI
    1. Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W. The ten-eleven translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia. 2014;28:485–96. - DOI
    1. Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94:1676–81. - DOI
    1. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009;114:3285–91. - DOI
    1. Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood. 2010;116:1132–5. - DOI

MeSH terms